Philip Morris International account plan
Developing smoke-free products
At a glance
Philip Morris International sells cigarettes and smoke-free products (IQOS, ZYN, VEEV): $40.6 billion 2025 net revenues, about 84,900 employees.
Philip Morris International (PMI) is a NYSE-listed tobacco and nicotine company that sells cigarettes, led by Marlboro, in approximately 170 markets and smoke-free products, mainly IQOS heat-not-burn, ZYN nicotine pouches and VEEV e-vapor, in 109 markets at June 30, 2026. Its stated goal is to completely end the sale of cigarettes. In 2025 net revenues were $40,648 million (+7.3%), operating income $14,892 million (+11.1%) and diluted EPS $7.26; smoke-free products made up 41.5% of net revenues. It had approximately 84,900 employees at December 31, 2025. Jacek Olczak is Group CEO.
Business units
International Smoke-Free
$7,713 million H1 2026 net revenuesIQOS heat-not-burn, ZYN and other oral nicotine, and VEEV e-vapor outside the U.S.; H1 2026 net revenues rose 19.2% with a 70% gross margin. IQOS holds a global heat-not-burn share of approximately 76%, and VEEV is number one in closed pods in Europe. Run within the PMI International business unit led by Frederic de Wilde.
International Combustibles
$12,147 million H1 2026 net revenuesCigarettes outside the U.S., led by Marlboro (about 43% of 2025 cigarette shipment volume, share 11.0% in Q2 2026); H1 2026 net revenues rose 8.4% on pricing, with growth in Turkey, Indonesia and Egypt offsetting declines in Europe.
U.S.
$1,478 million H1 2026 net revenuesZYN nicotine pouches, cigars, IQOS (sold in Austin, Texas while IQOS ILUMA awaits FDA action) and the Aspeya wellness unit; H1 2026 net revenues fell 16.1% after Q1 inventory movements. Led by Stacey Kennedy, CEO PMI U.S.
Strategic priorities
- Shift smokers to smoke-free products
- Reallocate resources from cigarettes to smoke-free products; 2026-2028 targets call for smoke-free shipment growth of high single digits to low teens.
- Re-accelerate ZYN in the U.S.
- Brand building, higher-strength products (ZYN Ultra 9mg and 11mg launched in June 2026) and a "360" U.S. investment push in the second half of 2026.
- Bring IQOS ILUMA to the U.S.
- The IQOS ILUMA PMTA/MRTPA filed October 2023 is still pending; PMI is preparing for launch subject to FDA action.
- Medium-term financial targets
- 2026-2028 CAGR targets: organic net revenue 6-8%, organic operating income 8-10% and currency-neutral adjusted EPS 9-11%.
- Cost savings and deleveraging
- Over $1.8 billion of cumulative gross cost savings toward $2 billion for 2024-2026, and adjusted leverage targeted close to 2x by end-2026 from 2.5x.
Latest results
In Q2 2026 net revenues rose 10.4% to $11,192 million (+7.6% organic), the first quarter above $11 billion, and operating income rose 22.0% to $4,530 million. Diluted EPS fell to $1.80 because of a $511 million impairment of the RBH (Canada) investment, while adjusted diluted EPS rose 15% to $2.20. International Smoke-Free shipments grew 8.0% to 44.7 billion units; Japan IQOS sales dipped after the April excise rise. 2026 guidance was kept at organic net revenue +5-7% and currency-neutral adjusted EPS +7.5-9.5%, with adjusted EPS of $8.26 to $8.41 and operating cash flow around $13.5 billion.
Investments and deals
- Smoke-free manufacturing capacity
- Capex was $1.6 billion in 2025, mainly smoke-free manufacturing capacity, and is guided at $1.4-1.6 billion for 2026; full-scale ZYN production began in Colorado.
- U.S. commercial investment
- A "When It Clicks" ZYN brand campaign, a ZYN-Ferrari global partnership and accelerated U.S. marketing, distribution and in-store investment in H2 2026.
- German factory restructuring
- $241 million of restructuring charges in 2025 to end combustible production in two German factories.
- Divestments
- Consumer accessories businesses sold or held for sale in Q4 2025, after the sale of Vectura on December 31, 2024.
Challenges and risks
- Smoke-free regulation
- Bans or severe restrictions in markets such as Brazil, India, Mexico and Australia, characterizing flavor bans in Poland and Hungary, the EU TPD revision and the UK generational sales ban bill adopted on April 29, 2026.
- Excise taxes
- Japan raised heated-tobacco excise on April 1 and October 1, 2026, and the EU Tobacco Excise Directive proposal would extend excise to smoke-free products from 2028.
- Slower U.S. ZYN growth
- Olczak said ZYN "is growing in The US, but it not growing at our expectations"; Q2 2026 U.S. shipments rose only 1.8%.
- Russia exposure
- Russia was around 6% of 2025 net revenues, and Russian operations held about $5.6 billion of assets at June 30, 2026.
- Illicit trade and cigarette decline
- Illicit trade is estimated at up to 15% of global cigarette consumption excluding China and the U.S., and cigarette shipments are expected to fall 2% to 3% in 2026.
What leadership says
“2025 was another outstanding year for PMI. The shift of adult smokers to better alternatives is a lasting structural movement, one that we continue to lead”
“AI is gonna be an engine for more efficiency and for cost performance in the future”
“after several quarters of frustration, it's a great moment”
“the underlying growth trend in Europe has not substantially changed”
Where a supplier can help
- U.S. go-to-market execution
- The "360" U.S. investment push for ZYN and the preparation for IQOS ILUMA create demand for retail execution, trade marketing, distribution and consumer-data partners.
- Cost-savings programme
- The $2 billion 2024-2026 gross cost-savings target, about 60% from COGS, and the CFO's view of AI as an efficiency engine open doors for procurement, automation and AI suppliers.
- Smoke-free manufacturing
- Capex of $1.4-1.6 billion in 2026, mainly smoke-free capacity, and ZYN production in Colorado point to equipment, packaging and electronics manufacturing services suppliers.
- Regulatory and compliance support
- Pending FDA applications, the EU TPD revision and flavor bans make regulatory science, compliance and age-verification providers relevant.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Philip Morris International?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Form 10-K for fiscal year 2025
- Philip Morris International (PMI) is a Virginia holding company, NYSE-listed since 2008, selling cigarettes in approximately 170 markets and smoke-free products (heat-not-burn IQOS, ZYN nicotine pouches, VEEV e-vapor) in 106 markets at December 31, 2025; about 84,900 employees.
- FY2025 net revenues were $40.6 billion (+7.3%, +6.5% excluding currency and acquisitions/divestitures); operating income $14,892 million (+11.1%); diluted EPS $7.26 (+60.6%, helped by the absence of the 2024 RBH impairment).
- Smoke-free net revenues reached $16.9 billion in 2025 vs $14.7 billion in 2024; smoke-free shipments grew 12.8% to 179.1 billion equivalent units while cigarettes fell 1.5% to 607.4 billion units.
- FY2025 segments by net revenue: Europe $17,111 million, SSEA, CIS & MEA $12,051 million, EA, AU & PMI GTR $6,632 million, Americas $4,854 million; Americas operating income fell 7.8% to $505 million on U.S. ZYN promotions and U.S. capability investments.
- From January 1, 2026 PMI runs two business units, International and U.S., reported as three segments: International Smoke-Free, International Combustibles and U.S.; Jacek Olczak became Group CEO, Frederic de Wilde CEO PMI International, Stacey Kennedy CEO PMI U.S.
- Marlboro was about 43% of 2025 cigarette shipment volume; PMI's international cigarette-and-HTU share was 29.2% (HTU 5.8%), excluding China and the U.S.
- 2026 outlook in the filing: broadly stable total shipments with high-single-digit SFP growth and around 3% cigarette decline; operating cash flow around $13.5 billion; capex $1.4-1.6 billion; effective tax rate around 21.5%.
- U.S. regulatory status: FDA authorized 20 ZYN varieties (January 2025); IQOS ILUMA PMTA/MRTPA filed October 2023 still pending; IQOS 3.0 sold in Austin, Texas since March 2025.
- Key risks: SFP regulation and flavor/sales bans, excise taxes (Japan HTP harmonization in April and October 2026, EU TED proposal), illicit trade, Russia (around 6% of net revenues, $4.8 billion of assets) and the Ukraine war.
- Balance sheet: total debt $48.8 billion; dividends paid $8.6 billion in 2025; annualized dividend rate $5.88 per share after an 8.9% increase.
- Form 10-Q for the quarter ended June 30, 2026
- Q2 2026 net revenues reached $11.2 billion (+10.4%, +7.6% excluding currency and acquisitions/divestitures); H1 2026 net revenues $21.3 billion (+9.8%, +5.3% organic).
- Q2 operating income $4,530 million (+22.0%); H1 operating income $8,423 million (+16.1%); H1 diluted EPS $3.36 (-8.4%), hit by a $511 million RBH impairment and equity-securities fair-value losses.
- First report under the new segments: H1 net revenues International Smoke-Free $7,713 million (+19.2%), International Combustibles $12,147 million (+8.4%), U.S. $1,478 million (-16.1%).
- Q2 International Smoke-Free shipments +8.0% to 44.7 billion units; IQOS shipments +7.6%; VEEV +55.1%; HTU adjusted IMS +5.1% (+10% excluding Japan and Poland).
- U.S.: Q2 ZYN shipments +1.8% to 2.9 billion pouches with flat to slightly growing offtake; ZYN ULTRA (9mg and 11mg) launched in June; U.S. investment to accelerate in H2, including preparation for IQOS ILUMA.
- FDA renewed IQOS exposure-modification orders (April 2026, to 2031) and authorized a modified-risk claim for 20 ZYN products (June 2026).
- 2026 shipment outlook raised to broadly stable to slightly growing, with cigarette decline of 2% to 3%; operating cash flow around $13.5 billion; capex $1.4-1.6 billion.
- Smoke-free products sold in 109 markets; ZYN in 61 markets; total debt $49.1 billion; Moody's outlook moved to Positive.
- Q4 and full-year 2025 earnings call transcript
- Jacek Olczak called 2025 "another outstanding year": smoke-free volumes +12.8%, smoke-free gross profit +18.7%, and adjusted diluted EPS +15% in dollar terms to $7.54.
- Smoke-free reached 41.5% of net revenues (close to $17 billion) and 43% of gross contribution; 27 markets exceed 50% smoke-free net revenues.
- PMI renewed its 2026-2028 targets: organic net revenue CAGR 6-8%, organic operating income 8-10%, currency-neutral adjusted EPS 9-11%, smoke-free volume growth high single digits to low teens.
- 2026 guidance: organic net revenue +5-7%, organic operating income +7-9%, currency-neutral adjusted EPS +7.5-9.5%; Q1 expected to be the softest quarter.
- Transitory 2026 headwinds: Japan's two HTP excise increases (April and October) and U.S. ZYN inventory comparisons; cigarette volumes forecast down around 3% with India and Mexico excise hikes.
- U.S. was around 7% of net revenues; ZYN shipments +37% to 794 million cans but growth below PMI's expectations; ZYN Ultra (higher strength, moist) awaited FDA action.
- IQOS adjusted IMS +12% in Q4; global heat-not-burn share around 76%; ZYN reached 56 markets and 13.6 billion pouches, a 2026 target hit a year early.
- Capital allocation: dividend payout near the 75% target, adjusted leverage 2.5x at end-2025 targeted close to 2x by end-2026; around $1.5 billion of gross cost savings since 2024 toward $2 billion.
- Q2 2026 earnings call transcript
- Emmanuel Babeau, in his last call as Group CFO, reported Q2 2026 organic net revenue +8% and operating income +11%, with adjusted diluted EPS $2.20 (+15% in dollar terms) and quarterly net revenues above $11 billion for the first time.
- H1 adjusted diluted EPS reached a record $4.16 (+15.6% in dollars, +9.4% excluding currency); international business was 93% of H1 group net revenues.
- International smoke-free H1 organic net revenue +13.7% and gross profit +16.9%, gross margin 70%; IQOS global heat-not-burn share approximately 76%; VEEV number one in Europe.
- Japan: Q2 IQOS adjusted IMS -3.4% after pantry de-loading around the April 1 excise rise; IQOS category share in the high 60s; a smaller pass-on (closer to 20 yen) expected for October.
- U.S.: ZYN shipments +2% to 2.9 billion pouches; ZYN Ultra 9mg and 11mg launched, 1.5mg and 8mg dry formats due in Q3; new "When It Clicks" campaign and a "360" U.S. investment push in H2.
- 2026 guidance kept: organic net revenue +5-7%, organic operating income +7-9%, currency-neutral EPS +7.5-9.5%; adjusted EPS range $8.26 to $8.41; combustible pricing now above 7%.
- Massimo Andolina (CFO from August 2026) attributes Europe's IQOS slowdown to flavor bans in Poland and Hungary and points to DELIA, LEVIA, VEEV and ZYN as the multi-category engine.
- Over $1.8 billion of cumulative gross cost savings toward the $2 billion 2024-2026 target.
Questions about Philip Morris International
What does Philip Morris International do?
PMI sells cigarettes, led by Marlboro, in approximately 170 markets and smoke-free products such as IQOS heated tobacco, ZYN nicotine pouches and VEEV e-vapor, with the stated goal of ending cigarette sales.
What is Philip Morris International's revenue?
Net revenues were $40,648 million in 2025, up 7.3%, with 41.5% from smoke-free products. H1 2026 net revenues were $21,338 million.
How many employees does Philip Morris International have?
Approximately 84,900 people worldwide at December 31, 2025.
Who leads Philip Morris International?
Jacek Olczak is Group CEO. Massimo Andolina became Group CFO in August 2026, succeeding Emmanuel Babeau; Frederic de Wilde runs PMI International and Stacey Kennedy PMI U.S.
What is PMI's strategy?
Move adult smokers to smoke-free products while keeping its cigarette position through selective investment, targeting organic net revenue growth of 6-8% a year over 2026-2028.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)